Le lymphome du manteau. http:/www.leucemie-espoir.org Tumor necrosis factor ? release is a major biological event associated with rituximab treatment, The Hematology Journal, vol.2, pp.378-384, 2001. ,
A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis, Cancer, vol.48, pp.198-206, 1981. ,
Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma ? a randomised phase II trial of the ,
and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) imporves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemia (abstract), Blood, vol.112, p.325, 2008. ,
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group classification of non-Hodgkin's lymphoma, Blood, vol.84, pp.1361-1392, 1994. ,
World Health Organization Classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, J Clin Oncol, vol.17, pp.3835-3849, 1997. ,
Commission de la transparence, Mabthera, avis. http://www.has-sante Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma, HAS J Clin Oncol, vol.26, 2008. ,
Developmental regulation of the bcl-2 protein and susceptibility to cell death in B lymphocytes, EMBOJ, vol.13, pp.683-691, 1994. ,
Results of treatment of advanced-stage Burkitt's lymphoma and B-cell stage (SIg+) acute lymphoblastic leukaemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine, J Clin Oncol, vol.4, pp.1732-1739, 1986. ,
Rituximab dose-escalation rial in chronic lymphocytic leukaemia, J Clin Oncol, vol.19, pp.2165-2170, 2001. ,
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine, J Clin Oncol, vol.23, pp.7013-7023, 2005. ,
Rituximab added to aIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients, Blood, vol.104, p.160, 2004. ,
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA- GOELAMS FL2000 study, Blood, vol.112, pp.4824-4831, 2008. ,
Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy, J Clin Oncol, vol.28, 2010. ,
Rituximab maintenance for 2 years significantly improves outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy : results of the PRIMA study ,
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia, Blood, vol.100, pp.3115-3120, 2002. ,
Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells, Cancer Res, vol.63, pp.534-540, 2003. ,
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura, Blood, vol.98, pp.952-957, 2001. ,
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody ,
Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma, Ann Hematol, vol.83, pp.120-123, 2004. ,
The treatment of indolent lymphomas: watchful waiting versus aggressive combined modality treatment, Semin Hematol, vol.25, pp.11-16, 1998. ,
Rituximab for the treatment of refractory autoimmune hemolytic anemia in children, Blood, vol.101, pp.3857-3861, 2003. ,
The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implication for therapy, The Oncologist, vol.13, pp.954-966, 2008. ,
Pcq maladie réfractaire (3) ni récidive ni réfractaire, en suivi de l'induction (4) Comme premier traitement de la maladie(5) Raison non disponible / NSP En traitement d'entretien Première dose de rituximab administrée ,
) en monothérapie (2) de la chimiothérapie en concomitance Dose de rituximab : [ ] (1) Dose 375 mg ,